Universidad Peruana Cayetano Heredia
Controversies in Systemic Lupus Erythematosus 2021 Changing the Paradigm in the Management of Lupus Nephritis
JavaScript is disabled for your browser. Some features of this site may not work without it.
Mostrar el registro sencillo del ítem
| dc.contributor.author | Porta, S. V. | |
| dc.contributor.author | Enfrein, A. | |
| dc.contributor.author | Houssiau, F. | |
| dc.contributor.author | Garcia, M. | |
| dc.contributor.author | Furie, R. | |
| dc.contributor.author | Rovin, B. H. | |
| dc.contributor.author | Alarcón, Graciela S. | |
| dc.contributor.author | Pons-Estel, B. A. | |
| dc.contributor.author | Pons-Estel, G. J. | |
| dc.date.accessioned | 2022-12-14T14:25:34Z | |
| dc.date.available | 2022-12-14T14:25:34Z | |
| dc.date.issued | 2022 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12866/12887 | |
| dc.description.abstract | Lupus nephritis (LN) affects about a third of patients with systemic lupus erythematosus. Although the use of conventional therapy has significantly improved the prognosis of LN, the response to treatment remains suboptimal, with high rates of relapse and the occurrence of end-stage kidney disease. The implementation of new diagnostic and treatment strategies aimed at improving these outcomes represents a necessary paradigm shift in the management of LN. Herein, we discuss different points of view regarding these still unresolved issues; these comments represent a debate that took place during the virtual congress of the Pan American League of Associations for Rheumatology (PANLAR) and which was organized by the PANLAR Lupus Study Group, GLADEL (Grupo Latino Americano De Estudio del Lupus) on August 15, 2021. | en_US |
| dc.language.iso | eng | |
| dc.publisher | Wolters Kluwer Health | |
| dc.relation.ispartofseries | Journal of Clinical Rheumatology | |
| dc.rights | info:eu-repo/semantics/restrictedAccess | |
| dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es | |
| dc.subject | systemic lupus erythematosus | en_US |
| dc.subject | lupus nephritis | en_US |
| dc.subject | mycophenolate mofetil | en_US |
| dc.subject | biopsy | en_US |
| dc.subject | belimumab | en_US |
| dc.subject | voclosporin | en_US |
| dc.title | Controversies in Systemic Lupus Erythematosus 2021 Changing the Paradigm in the Management of Lupus Nephritis | en_US |
| dc.type | info:eu-repo/semantics/article | |
| dc.identifier.doi | https://doi.org/10.1097/RHU.0000000000001859 | |
| dc.relation.issn | 1536-7355 |
Ficheros en el ítem
| Ficheros | Tamaño | Formato | Ver |
|---|---|---|---|
|
No hay ficheros asociados a este ítem. |
|||
Este ítem aparece en la(s) siguiente(s) colección(ones)
-
Artículos en revistas indizadas [4988]
Recuperados de bases de datos bibliográficas
Excepto si se señala otra cosa, la licencia del ítem se describe como info:eu-repo/semantics/restrictedAccess
